Work

Efficacy and Safety of Epicutaneous Immunotherapy in Peanut-Allergic Toddlers: Open-Label Extension to EPITOPE

Year: 2025
Type: article
Abstract: BACKGROUND: The pivotal phase 3 EPITOPE trial, a 12-month, double-blind, placebo-controlled study of epicutaneous immunotherapy with the VIASKIN patch containing 250 μg of peanut protein (VP250), previously reported significant treatment response versus placebo in peanut-allergic toddlers aged 1 through 3 years. OBJECTIVE: To assess the interim efficacy and safety of VP250 from the first year of the EPITOPE open-label extension (OLE) study. METHODS: Eligible participants enrolled in the OLE study for up to 3 years of total treatment with annual double-blind, placebo-controlled food challenges (DBPCFCs) and safety assessments; here we report the first-year OLE (year 2) results. RESULTS: A total of 266 EPITOPE participants enrolled in the OLE study; 244 underwent month 24 DBPCFC (n = 166 VP250; n = 78 placebo). After 24 months of VP250, 81.3% reached an eliciting dose (ED) ≥1000 mg, 63.8% reached an ED ≥2000 mg, and 55.9% completed the DBPCFC (cumulative dose: 3444 mg) without meeting stopping criteria. No treatment-related anaphylaxis or serious treatment-related adverse events occurred during year 2 in this treatment arm. Local application-site reactions occurred less frequently in year 2 versus year 1. In placebo-treated EPITOPE participants, outcomes after 1 year of open-label VP250 were consistent with EPITOPE treatment results: 62.7% reached an ED ≥1000 mg, 36.5% reached an ED ≥2000 mg, and 28.4% completed the DBPCFC without meeting stopping criteria; and there was 1 treatment-related anaphylaxis event. CONCLUSIONS: Two years of VP250 in young peanut-allergic children demonstrated continued increases in treatment effect without new safety signals. This supports the potential of VP250 as a safe and effective treatment for peanut allergy in young children. CLINICALTRIALS: GOV: NCT03859700.
Institutions: Children's Hospital Colorado, University of Colorado Anschutz, University of Pittsburgh, Children's Hospital of Pittsburgh, University of Pittsburgh Medical Center, Baylor College of Medicine, Texas Children's Hospital, Erasmus MC - Sophia Children’s Hospital, University of Manchester, Centre Hospitalier Universitaire Sainte-Justine, Université de Montréal, Goethe University Frankfurt, Children's Hospital of Philadelphia, University of Pennsylvania, Banner - University Medical Center Tucson, University of British Columbia, BC Children's Hospital, University of Chicago, Centre National de la Recherche Scientifique, Inserm, Université de Lille, Institut Pasteur de Lille, Centre Hospitalier Universitaire de Lille, Center for Infection and Immunity of Lille, Centre Hospitalier Régional et Universitaire de Nancy, Développement, Adaptation et Handicap, Université de Lorraine, Vanderbilt University Medical Center, University of California, San Francisco, Guy's and St Thomas' NHS Foundation Trust, University of Toronto, Hospital for Sick Children, Universitätsklinikum St. Pölten, Karl Landsteiner University of Health Sciences, University Hospital Southampton NHS Foundation Trust, Southampton Children's Hospital, The University of Sydney, Children's Hospital at Westmead, University of California, Los Angeles, Royal College of Surgeons in Ireland, Sheffield Children's NHS Foundation Trust, Arkansas Children's Hospital, University of Arkansas for Medical Sciences, University of North Carolina at Chapel Hill, Indiana University Health, Indiana University Hospital, Riley Hospital for Children, University of California San Diego, Hôpital Necker-Enfants Malades, Université Paris Cité, Assistance Publique – Hôpitaux de Paris, University of Tennessee Health Science Center, Le Bonheur Children's Hospital, University of Rochester Medicine, University of Rochester, Northwestern University, Lurie Children's Hospital, The Kids Research Institute Australia, Princess Margaret Hospital for Children, Perth Children's Hospital, Children's Medical Center, The University of Texas Southwestern Medical Center, The University of Queensland, Children's Health Queensland Hospital and Health Service, Royal Children's Hospital, The University of Melbourne, Murdoch Children's Research Institute, BioCryst Pharmaceuticals (United States), Women's and Children's Hospital, Women's and Children's Health Network, Vanderbilt University, University of Michigan, Boston Children's Hospital, Harvard University, Children's National, Stanford University, University College Cork, Cork University Hospital, Infant, Imperial College London, Golisano Children's Hospital, Dell Children's Medical Center of Central Texas, The University of Texas at Austin, Emory University, Children's Healthcare of Atlanta, University Hospital Carl Gustav Carus, Technische Universität Dresden, UNSW Sydney, Sydney Children's Hospital, Icahn School of Medicine at Mount Sinai, Johns Hopkins University, Johns Hopkins Medicine, DBV Technologies (France)
Language: English
Field: Medicine
Open Access status: hybrid
Estimated APC paid: $4,000
OpenAlex ID: W4407572947
FWCI: 12.27
Cites: 29
Cited by: 20
Related to: 10